A citation-based method for searching scientific literature

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele. Lancet Oncol 2020
Times Cited: 153



Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi, Benjamin Besse, Sant P Chawla, Lyudmila Bazhenova, John C Krauss, Young Kwang Chae, Minal Barve, Ignacio Garrido-Laguna, Stephen V Liu, Paul Conkling, Thomas John, Marwan Fakih, Darren Sigal, Herbert H Loong, Gary L Buchschacher, Pilar Garrido, Jorge Nieva, Conor Steuer, Tobias R Overbeck, Daniel W Bowles, Elizabeth Fox, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, George D Demetri. Lancet Oncol 2020
Times Cited: 421




List of shared articles



Times cited

Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs.
Diego Kauffmann-Guerrero, Amanda Tufman. Curr Opin Oncol 2022
1

Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases.
Aaron C Tan, Drexell H Boggs, Eudocia Q Lee, Michelle M Kim, Minesh P Mehta, Mustafa Khasraw. Front Oncol 2022
0

Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Francois Mercier, Nassim Djebli, Mario González-Sales, Felix Jaminion, Georgina Meneses-Lorente. Cancer Chemother Pharmacol 2022
0

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Aaron C Tan, Sze Huey Tan, Siqin Zhou, Solange Peters, Giuseppe Curigliano, Daniel S W Tan. Cancer Treat Rev 2022
0

Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Ian M Silverman, Meijuan Li, Karthikeyan Murugesan, Melanie A Krook, Milind M Javle, Robin K Kelley, Mitesh J Borad, Sameek Roychowdhury, Wei Meng, Bahar Yilmazel,[...]. J Mol Diagn 2022
0

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022
0

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, Voleak Choeurng, Alexander Drilon, Robert C Doebele, Fabrice Barlesi, Charlie Wu, Lucas Dennis, Joel Skoletsky,[...]. Mol Oncol 2022
0

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Entrectinib, a new multi-target inhibitor for cancer therapy.
Qinghua Jiang, Mingxue Li, Hua Li, Lixia Chen. Biomed Pharmacother 2022
1

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman. Int J Mol Sci 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis.
Ruchir Raman, Varun Ramamohan, Anurag Rathore, Deepali Jain, Anant Mohan, Vishal Vashistha. Asia Pac J Clin Oncol 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

Application of Next Generation Sequencing in Laboratory Medicine.
Yiming Zhong, Feng Xu, Jinhua Wu, Jeffrey Schubert, Marilyn M Li. Ann Lab Med 2021
24

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
4

Mitteilungen der Deutschen Gesellschaft für Pathologie.
. Pathologe 2021
0

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
64

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
1

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
23

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
J Delgado, E Pean, D Melchiorri, C Migali, F Josephson, H Enzmann, F Pignatti. ESMO Open 2021
2

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
8

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
James E Frampton. Drugs 2021
1

Evolving role of entrectinib in treatment of NTRK-positive tumors.
Neal Chawla, Nam Q Bui, Mahesh Seetharam. Future Oncol 2021
0

The evolving paradigm of precision medicine in lung cancer.
Francesco Passiglia, Giorgio V Scagliotti. Curr Opin Pulm Med 2021
0

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
10

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
18

Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Matthew K Stein, Oluchukwu Oluoha, Kruti Patel, Ari VanderWalde. J Pers Med 2021
4

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier. Int J Mol Sci 2021
7

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
81

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Pamela Abdayem, David Planchard. Eur Respir Rev 2021
0

Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC.
Robert C Doebele, Laura Perez, Huong Trinh, Michael Martinec, Reynaldo Martina, Todd Riehl, Matthew G Krebs, Neal J Meropol, William B Wong, Gracy Crane. J Comp Eff Res 2021
2

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Nassim Djebli, Vincent Buchheit, Neil Parrott, Elena Guerini, Yumi Cleary, Stephen Fowler, Nicolas Frey, Li Yu, François Mercier, Alex Phipps,[...]. Eur J Drug Metab Pharmacokinet 2021
1

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów, Piotr Dzięgiel. Cancers (Basel) 2021
10


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy